catalyst

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cogni — primary completion

as of 2026-07-01
Monitor thisAsk about this
at a glance
2015-10 · Actual — This event happened.
Synthesized from structured facts only — each point cited above.

Event

What
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cogni — primary completion
Type
Trial Readout
Date
2015-10
Date type
ACTUAL
Phase
Phase 3
This event happened.
relationships
The graph out of here
trial
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
trial